NVS: Novartis AG Stocks News on September 1, 2025

Novartis (NVS) Strengthens Outlook With Ianalumab Trial Success and Leqvio Expansion

NVS

Insider Monkey

20 hours ago

Novartis (NVS) Strengthens Outlook With Ianalumab Trial Success and Leqvio Expansion

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

NVS

GlobeNewswire

a day ago

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

The Bull Case For Legend Biotech (LEGN) Could Change Following Appointment of CFO With Global Pharma Expertise

NVS

Simply Wall St.

2 days ago

The Bull Case For Legend Biotech (LEGN) Could Change Following Appointment of CFO With Global Pharma Expertise

Gateway to Growth: Innovation and Opportunity at the 8th CIIE

NVS

PR Newswire

3 days ago

Gateway to Growth: Innovation and Opportunity at the 8th CIIE

Eli Lilly’s Verzenio boosts OS in breast cancer as Novartis rivalry heats up

NVS

Clinical Trials Arena

3 days ago

Eli Lilly’s Verzenio boosts OS in breast cancer as Novartis rivalry heats up

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

NVS

Zacks

4 days ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Binge Eating Disorders Global Market Research Report 2025-2035 Featuring Eli Lilly, Amneal, Takeda, Tryp Therapeutics, Tonix, Sumitomo, VIVUS, Novartis, and Pfize

NVS

GlobeNewswire

5 days ago

Binge Eating Disorders Global Market Research Report 2025-2035 Featuring Eli Lilly, Amneal, Takeda, Tryp Therapeutics, Tonix, Sumitomo, VIVUS, Novartis, and Pfize

Amylyx drug comes up short; Sanofi names new CMO

NVS

BioPharma Dive

5 days ago

Amylyx drug comes up short; Sanofi names new CMO

HER2+ Breast Cancer Clinical Trials Analysis Report 2025 - Enhance Your Understanding of Trial Counts and Enrollment Trends Across G7 & E7 Countries

NVS

GlobeNewswire

5 days ago

HER2+ Breast Cancer Clinical Trials Analysis Report 2025 - Enhance Your Understanding of Trial Counts and Enrollment Trends Across G7 & E7 Countries

Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic

NVS

GlobeNewswire

5 days ago

Dyslipidemia Market Research Report 2025-2035 | Competitive Analysis of Amgen, Sanofi, Regeneron, Pfizer, Novartis, Viatris, AbbVie, AstraZeneca, Horizon Therapeutics, Esperion Therapeutic

Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma

NVS

GlobeNewswire

5 days ago

Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun Pharma

Autism Spectrum Disorder Market Research Report 2025-2035 | Expansion Spurred by Rising Prevalence, AI-Powered Diagnostics, Telehealth Expansion, and Adoption of Evidence-Based Therapies

NVS

GlobeNewswire

5 days ago

Autism Spectrum Disorder Market Research Report 2025-2035 | Expansion Spurred by Rising Prevalence, AI-Powered Diagnostics, Telehealth Expansion, and Adoption of Evidence-Based Therapies

NVS

MT Newswires

5 days ago

Novartis Commits $30 Million to BioArctic in BrainTransporter Licensing Pact

Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?

NVS

Zacks

6 days ago

Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?

Should Investors Rethink Tempus AI After Shares Double and New Novartis Collaboration?

NVS

Simply Wall St.

6 days ago

Should Investors Rethink Tempus AI After Shares Double and New Novartis Collaboration?

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties

NVS

PR Newswire

6 days ago

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties

RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

NVS

Zacks

6 days ago

RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

NVS

The Wall Street Journal

9 days ago

Health Care Roundup: Market Talk

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

NVS

GlobeNewswire

10 days ago

[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Leqvio® advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance

NVS

CNW Group

11 days ago

Leqvio® advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance

NVS

Morningstar Research

11 days ago

Analyst Report: Alcon Inc.

INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?

NVS

Zacks

11 days ago

INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?

QuisLex Appoints Alok Priyadarshi as Vice President, Strategic AI Advisory and Legal Transformation for QuisLex Advisory

NVS

GlobeNewswire

12 days ago

QuisLex Appoints Alok Priyadarshi as Vice President, Strategic AI Advisory and Legal Transformation for QuisLex Advisory

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

NVS

Zacks

13 days ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Will EXEL's Share Repurchase Program Boost Value for Investors?

NVS

Zacks

13 days ago

Will EXEL's Share Repurchase Program Boost Value for Investors?

Atropos Health Enters into Strategic Collaboration to Reduce Time to Rare Disease Diagnosis with Artificial Intelligence (AI) Algorithm

NVS

Business Wire

14 days ago

Atropos Health Enters into Strategic Collaboration to Reduce Time to Rare Disease Diagnosis with Artificial Intelligence (AI) Algorithm

New Novartis ESC data highlights strength of cardiovascular portfolio

NVS

GlobeNewswire

14 days ago

New Novartis ESC data highlights strength of cardiovascular portfolio

Geron Corporation Names Harout Semerjian as New CEO to Lead Commercialization of RYTELO

NVS

Insider Monkey

14 days ago

Geron Corporation Names Harout Semerjian as New CEO to Lead Commercialization of RYTELO

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm

NVS

Motley Fool

14 days ago

Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm

NVS

Motley Fool

17 days ago

2 Dividend Stocks to Buy and Hold

NVS

MT Newswires

17 days ago

Sector Update: Health Care Stocks Rise Late Afternoon

NVS

MT Newswires

18 days ago

Novartis, Roche Reportedly Meet With Swiss Government Over US Tariffs

Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB

NVS

GlobeNewswire

19 days ago

Saudi Arabia Osteoporosis Drugs Market Analysis Report 2025-2033 Featuring Amgen, Eli Lilly and Co, F. Hoffmann La Roche, GlaxoSmithKline, Merck, Novartis, Pfizer, Teva Pharmaceutical, UCB

Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?

NVS

Zacks

19 days ago

Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?

NVS

Morningstar Research

19 days ago

Analyst Report: Incyte Corporation

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

NVS

Zacks

20 days ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Quantified Named to 2025 Inc. 5000, One of the 50 Fastest-Growing AI Firms in the U.S.

NVS

PR Newswire

20 days ago

Quantified Named to 2025 Inc. 5000, One of the 50 Fastest-Growing AI Firms in the U.S.

Novartis scores again with third ianalumab Phase III victory

NVS

Clinical Trials Arena

20 days ago

Novartis scores again with third ianalumab Phase III victory

Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda

NVS

GlobeNewswire

20 days ago

Multiple Myeloma Market Trends and Company Analysis Report 2025-2033 Featuring BMS, Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, and Takeda

NVS

The Wall Street Journal

20 days ago

Health Care Roundup: Market Talk

NVS

Investing.com

20 days ago

Novartis shares slightly up after Ianalumab meets goals in Phase 3 trial

Novartis’s Ianalumab Meets Goals in Phase 3 Trial to Treat Autoimmune Disease

NVS

The Wall Street Journal

20 days ago

Novartis’s Ianalumab Meets Goals in Phase 3 Trial to Treat Autoimmune Disease

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

NVS

GlobeNewswire

20 days ago

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

NVS

MT Newswires

20 days ago

Sector Update: Health Care Stocks Rise Late Afternoon

NVS

MT Newswires

21 days ago

Sector Update: Health Care Stocks Rise Premarket Monday

Rheinmetall, Ørsted, Novartis: Global Stocks in Focus

NVS

The Wall Street Journal

21 days ago

Rheinmetall, Ørsted, Novartis: Global Stocks in Focus

NVS

MT Newswires

21 days ago

Novartis Says Phase III Sjogren's Disease Trials Meet Primary Endpoint

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease

NVS

PR Newswire

21 days ago

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease

How Switzerland’s tariff drama swung from hope to despair

NVS

Bloomberg

23 days ago

How Switzerland’s tariff drama swung from hope to despair

NVS

MT Newswires

23 days ago

Sector Update: Health Care Stocks Climb Late Afternoon

NVS

MT Newswires

23 days ago

Novartis Shares Higher After Morgan Stanley Upgrade

Switzerland says tariff talks with US continue, gold industry concerned about bullion trade

NVS

Reuters

23 days ago

Switzerland says tariff talks with US continue, gold industry concerned about bullion trade

NVS

MT Newswires

24 days ago

Morgan Stanley Upgrades Novartis to Equalweight From Underweight, Adjusts Price Target to $123 From $100

Chronic Obstructive Pulmonary Disease Treatment Devices Market Insights, Competitive Landscape, and Market Forecast 2024-2032

NVS

GlobeNewswire

24 days ago

Chronic Obstructive Pulmonary Disease Treatment Devices Market Insights, Competitive Landscape, and Market Forecast 2024-2032

Renal Transplant Therapeutics Market Insights, Competitive Landscape, and Forecast Report 2024-2032 | Calcineurin Inhibitors Dominate Renal Transplant Therapeutics Market

NVS

GlobeNewswire

24 days ago

Renal Transplant Therapeutics Market Insights, Competitive Landscape, and Forecast Report 2024-2032 | Calcineurin Inhibitors Dominate Renal Transplant Therapeutics Market

NVS

Morningstar Research

24 days ago

Analyst Report: Intellia Therapeutics, Inc.

NVS

Investing.com

24 days ago

Genmab raises full-year outlook, shares rise

United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda

NVS

GlobeNewswire

25 days ago

United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda

Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical

NVS

GlobeNewswire

25 days ago

Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical

Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal

NVS

Investor's Business Daily

25 days ago

Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal

NVS

MT Newswires

25 days ago

Sector Update: Health Care Stocks Slide Late Afternoon

NVS

MT Newswires

25 days ago

Sector Update: Health Care Stocks Fall Wednesday Afternoon

NVS

MT Newswires

25 days ago

Sector Update: Health Care

Teva’s Ajovy becomes first migraine prevention drug approved for children

NVS

Pharmaceutical Technology

25 days ago

Teva’s Ajovy becomes first migraine prevention drug approved for children

Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry

NVS

GlobeNewswire

25 days ago

Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry

American Kidney Fund Expands ‘Me + C3G’ Campaign with New Resources to Help Patients Living with this Rare Kidney Disease

NVS

GlobeNewswire

a month ago

American Kidney Fund Expands ‘Me + C3G’ Campaign with New Resources to Help Patients Living with this Rare Kidney Disease

United States Smart Pills Market Research and Company Analysis Report 2025-2033 Featuring Check-Cap, General Electric, Fujifilm, Koninklijke Philips, Medtronic, Olympus, Novartis, Otsuka

NVS

GlobeNewswire

a month ago

United States Smart Pills Market Research and Company Analysis Report 2025-2033 Featuring Check-Cap, General Electric, Fujifilm, Koninklijke Philips, Medtronic, Olympus, Novartis, Otsuka

Saudi Arabia Vision Care Market Forecast and Company Analysis Report 2025-2033 Featuring Essilor, J&J, Bausch Health, Novartis, Grand Vision, Carl Zeiss, Valeant, Paragon Vision Science, Menicon

NVS

GlobeNewswire

a month ago

Saudi Arabia Vision Care Market Forecast and Company Analysis Report 2025-2033 Featuring Essilor, J&J, Bausch Health, Novartis, Grand Vision, Carl Zeiss, Valeant, Paragon Vision Science, Menicon

[Latest] Global Paracetamol Market Size/Share Worth USD 1460.23 Million by 2034 at a 5.24% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

NVS

GlobeNewswire

a month ago

[Latest] Global Paracetamol Market Size/Share Worth USD 1460.23 Million by 2034 at a 5.24% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?

NVS

Zacks

a month ago

Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?

Swiss Stocks Decline on US Tariffs, Push for Lower Drug Prices

NVS

Bloomberg

a month ago

Swiss Stocks Decline on US Tariffs, Push for Lower Drug Prices

Swiss Gird for Stocks to Fall as Markets Reopen After Tariff Hit

NVS

Bloomberg

a month ago

Swiss Gird for Stocks to Fall as Markets Reopen After Tariff Hit

Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target

NVS

Insider Monkey

a month ago

Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target

ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up

NVS

Zacks

a month ago

ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up

Switzerland, the land of luxury brands, could see prices skyrocket from Trump's 39% tariffs

NVS

Associated Press Finance

a month ago

Switzerland, the land of luxury brands, could see prices skyrocket from Trump's 39% tariffs

Global Pharma Stocks Fall After Trump Demands Cuts in Drug Prices

NVS

The Wall Street Journal

a month ago

Global Pharma Stocks Fall After Trump Demands Cuts in Drug Prices

Trump Unleashes Massive Tariffs on Swiss Watches, Pharma Firms

NVS

Bloomberg

a month ago

Trump Unleashes Massive Tariffs on Swiss Watches, Pharma Firms

Trump doubles down on Most Favored Nation plan to target drug prices

NVS

Pharmaceutical Technology

a month ago

Trump doubles down on Most Favored Nation plan to target drug prices

Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

NVS

PR Newswire

a month ago

Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use

What Trump's Big Pharma CEO letters mean for drug pricing power

NVS

Yahoo Finance Video

a month ago

What Trump's Big Pharma CEO letters mean for drug pricing power

Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs

NVS

The Wall Street Journal

a month ago

Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs

NVS

Morningstar Research

a month ago

Analyst Report: Haleon plc

Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook

NVS

Zacks

a month ago

Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook

Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas

NVS

GlobeNewswire

a month ago

Renal Failure Clinical Trials Market Landscape Report 2025 Featuring Bayer, AstraZeneca, Amgen, Sanofi, Novartis, AbbVie, Roche, Pfizer, Takeda, Astellas

Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA

NVS

GlobeNewswire

a month ago

Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA

Systemic Lupus Erythematosus Clinical Trials Market Landscape Report 2025 Featuring GSK, BMS, AstraZeneca, Thermo Fisher Scientific, ICON, IQVIA, Parexel, Laboratory Corp of America, Novartis, Pfizer

NVS

GlobeNewswire

a month ago

Systemic Lupus Erythematosus Clinical Trials Market Landscape Report 2025 Featuring GSK, BMS, AstraZeneca, Thermo Fisher Scientific, ICON, IQVIA, Parexel, Laboratory Corp of America, Novartis, Pfizer

Sicca Syndrome (Sjogren) Clinical Trials Market Landscape Report 2025 Featuring Novartis, BMS, ICON, AbbVie, Parexel, Thermo Fisher Scientific, Amgen, Laboratory Corp of America, IQVIA, Syneos Health

NVS

GlobeNewswire

a month ago

Sicca Syndrome (Sjogren) Clinical Trials Market Landscape Report 2025 Featuring Novartis, BMS, ICON, AbbVie, Parexel, Thermo Fisher Scientific, Amgen, Laboratory Corp of America, IQVIA, Syneos Health

Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON

NVS

GlobeNewswire

a month ago

Mycosis Fungoides Clinical Trials Market Landscape Report 2025 Featuring Pfizer, Bristol-Myers Squibb, Kirin, Takeda, Johnson & Johnson, Merck, Soligenix, Eisai, Novartis, ICON

Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health

NVS

GlobeNewswire

a month ago

Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health

NVS

Morningstar Research

a month ago

Analyst Report: Incyte Corporation

INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales

NVS

Zacks

a month ago

INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales

Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival

NVS

BioPharma Dive

a month ago

Radiopharma startup Artbio secures $132M to fund testing of Pluvicto rival

HS market forecast to reach $7.8bn across 7MM by 2034

NVS

Pharmaceutical Technology

a month ago

HS market forecast to reach $7.8bn across 7MM by 2034

NVS

Zacks

a month ago

Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?

AAV for the Hereditary Retinal Diseases Market Competitive Landscape Report 2025 | Novartis, MeiraGTx, 4D Molecular Therapeutics, and Beacon Therapeutics Lead the Charge in Innovative Therapies

NVS

GlobeNewswire

a month ago

AAV for the Hereditary Retinal Diseases Market Competitive Landscape Report 2025 | Novartis, MeiraGTx, 4D Molecular Therapeutics, and Beacon Therapeutics Lead the Charge in Innovative Therapies

Myeloproliferative Disorder Treatment Market Insights, Competitive Landscape, and Forecast Report 2025-2032 Featuring Novartis, Incyte, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia

NVS

GlobeNewswire

a month ago

Myeloproliferative Disorder Treatment Market Insights, Competitive Landscape, and Forecast Report 2025-2032 Featuring Novartis, Incyte, Bristol Myers Squibb, CTI BioPharma, GSK, PharmaEssentia

Post-Operative Nausea and Vomiting Market Report 2025: Surge in Surgical Procedures Fuels $2.97 Billion Growth in PONV Market by 2029

NVS

GlobeNewswire

a month ago

Post-Operative Nausea and Vomiting Market Report 2025: Surge in Surgical Procedures Fuels $2.97 Billion Growth in PONV Market by 2029

Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?

NVS

Zacks

a month ago

Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?

Fibroblast Growth Factors (FGFs) Global Market Report 2025-2029 & 2034 | Regenerative Medicine Demand and Biotech Advancements Fueling Expansion

NVS

GlobeNewswire

a month ago

Fibroblast Growth Factors (FGFs) Global Market Report 2025-2029 & 2034 | Regenerative Medicine Demand and Biotech Advancements Fueling Expansion

NVS

MT Newswires

a month ago

Latest Novartis AG (NVS) News on September 1, 2025

Share on Social Networks: